The role of androgens as a key driver of prostate carcinogenesis has been known for 50 years. In the early 1990s, with the development of finasteride, a selective inhibitor of the type 2 isoenzyme of 5α-reductase (5-AR) that lowers intraprostatic dihydrotestosterone levels, it was hypothesized that 5-AR inhibition might prevent prostate cancer. Two phase 3 studies, the Prostate Cancer Prevention Trial (PCPT) 1 Subsequent studies confirmed the first and fourth theories; the first theory appeared to not be operative, and the second was the clinical result.
and placebo-controlled trial enrolled 18 882 men 55 years or older with a normal digital rectal examination (DRE) result and serum prostate-specific antigen (PSA) level of 3.0 ng/mL or lower (to convert to micrograms per liter, multiply by 1) and assigned them to treatment with finasteride, 5 mg/d, or placebo for 7 years. Prostate biopsies were performed in men for cause (abnormal prostate examination result or PSA level >4.0 ng/mL) and in cancer-free men at the end of 7 years of treatment. Results of the PCPT were reported in 2003. 1 Based on recommendations of an independent data and safety monitoring committee, a decision was made to close the study because there was convincing evidence that the primary study objective had been met: a significantly reduced risk of prostate cancer. Finasteride reduced the prevalence of prostate cancer by 24.8%. 1 The prevalence of Gleason grade 7 to 10 cancers was 6.4% in the finasteride group compared with 5.1% in the placebo group. Risk reduction in prostate cancer was apparent in men undergoing biopsy for cause and in men undergoing end-of-study biopsy. Prostate volumes were 24% smaller in men taking finasteride than in those receiving placebo. The concerning finding of the study was the higher prevalence of Gleason grade 7 to 10 cancers in the finasteride group. Subsequent studies confirmed the first and fourth theories; the first theory appeared to not be operative, and the second was the clinical result. [4] [5] [6] The REDUCE trial randomized 8231 men aged 50 to 75 years at higher risk of prostate cancer (ie, PSA level, 2.5-10.0 ng/mL) with 1 recent negative prostate biopsy result to dutasteride, 0.5 mg/d, or placebo.
2 After 4 years, among the 6729 men who had undergone at least 1 prostate biopsy, 25.1% of the placebo group and 19.9% of the dutasteride group had been diagnosed as having prostate cancer, a statistically significant difference paralleling the PCPT results. 2 The REDUCE trial initially concluded that over the 4 years of the trial there was no significant increase in the incidence of tumors with Gleason grade 7 to 10 in the dutasteride group compared with the placebo group; however, during years 3 and 4, there were 12 tumors with a Gleason grade 8 to 10 in the dutasteride group compared with only 1 in the placebo group (P = .003). Subsequent pathologic reassessment by the US Food and Drug Administration (FDA) detected an absolute increase of 0.5% and 0.7% in the incidence of highgrade (Gleason grade 8-10) cancer with dutasteride and finasteride, respectively.
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In 2011, the FDA not only denied the application for dutasteride as a chemoprevention agent, a warning of a potential for increased risk of high-grade prostate cancer with the use of 5-AR inhibitors (5-ARIs) used in the treatment of benign prostatic hypertrophy was issued. On the basis of this package insert warning, some physicians changed their practice to minimize the use of 5-ARIs for men who could benefit from their use. Since then, few studies have provided insight into whether such a concern was warranted.
As reported in this issue of JAMA Oncology, Azoulay and colleagues 8 took a unique approach to address this controversy.
Rather than reanalyze the 2 prevention trials and assess survival at later time points, they looked at 4 linked health care databases from the United Kingdom. This allowed them to analyze 13 892 men with newly diagnosed prostate cancer between a 10-year period. Their hypothesis was that men who had received a 5-ARI prior to the diagnosis of prostate cancer should be more commonly diagnosed as having high-grade disease and ultimately have worse outcomes. After 4.5 years of follow-up, 5001 deaths occurred in the study population, with 2439 deaths from prostate cancer. They found that 5-ARI use before the diagnosis of prostate cancer was not associated with an increased risk of prostate cancer-specific mortality or all-cause mortality. These results augment the long-term follow-up findings of the PCPT, showing no mortality increase in the finasteride group.
